Although substantial advances have been made in the treatment of genetically defined subtypes, such as RAS/BRAF wild-type (4) and BRAFMT colorectal cancer (5), an effective therapeutic strategy for KRASMT colorectal cancer, the most common genetically defined subtype (∼40%–45%) is still lacking. Here, BRAF is linked to colorectal cancer.